Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors
作者:Abdallah E. Abdallah、Reda R. Mabrouk、Maged Mohammed Saleh Al Ward、Sally I. Eissa、Eslam B. Elkaeed、Ahmed B. M. Mehany、Mariam A. Abo-Saif、Ola A. El-Feky、Mohamed S. Alesawy、Mohamed Ayman El-Zahabi
DOI:10.1080/14756366.2021.2017911
日期:2022.12.31
Abstract Based on quinazoline, quinoxaline, and nitrobenzene scaffolds and on pharmacophoric features of VEGFR-2 inhibitors, 17 novel compounds were designed and synthesised. VEGFR-2 IC50 values ranged from 60.00 to 123.85 nM for the new derivatives compared to 54.00 nM for sorafenib. Compounds 15a, 15b, and 15d showed IC50 from 17.39 to 47.10 µM against human cancer cell lines; hepatocellular carcinoma
抽象的 基于喹唑啉、喹喔啉和硝基苯支架以及VEGFR-2抑制剂的药效团特征,设计并合成了17种新型化合物。新衍生物的 VEGFR-2 IC 50值范围为 60.00 至 123.85 nM,而索拉非尼的 IC 50 值为 54.00 nM。化合物15a 、 15b和15d对人癌细胞系的IC 50为17.39至47.10μM;肝细胞癌 (HepG2)、前列腺癌 (PC3) 和乳腺癌 (MCF-7)。同时,在VEGFR-2抑制方面第一的是化合物15d ,其在抗肿瘤测定方面位居第二,针对上述细胞系的IC 50分别为24.10、40.90和33.40μM。此外,化合物15d使 HepG2 的凋亡率从 1.20% 增加至 12.46%,因为它使 Caspase-3、BAX 和 P53 的水平分别从 49.6274、40.62 和 42.84 显着增加到 561.427、395.04 和 415.027